Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6173704 | 0.91 | IGF1R (0.45) | IGF1RAR | |
| SCHEMBL6177313 | 0.89 | IGF1R (0.45) | IGF1R | |
| SCHEMBL6174494 | 0.87 | IGF1R (0.42) | IGF1RAR | |
| SCHEMBL6175683 | 0.87 | IGF1R (0.51) | IGF1RAR | |
| SCHEMBL6172820 | 0.87 | IGF1R (0.42) | IGF1RAR | |
| SCHEMBL6174175 | 0.87 | IGF1R (0.55) | IGF1RAR | |
| SCHEMBL6174595 | 0.86 | IGF1R (0.52) | IGF1RAR | |
| SCHEMBL6173683 | 0.86 | IGF1R (0.52) | IGF1RAR | |
| SCHEMBL6173508 | 0.86 | IGF1R (0.56) | IGF1RAR | |
| SCHEMBL6175196 | 0.86 | IGF1R (0.45) | IGF1RAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3188729-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | Genzyme Corporation (US) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016036796-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION (US) | 2016-03-10 | — | — | WO | disclosed |
| EP-1599464-A2 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004070050-A2 | CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | WO | disclosed |